COVID-19 Summit Sees Progress On Test-And-Treat, IP Licensing, & Funding Commitments
$712m More Pledged For World Bank Pandemic Preparedness Fund
Announcements at the second Global COVID-19 Summit included a technology licensing agreement for vaccine and diagnostic products developed by the US NIH, a new partnership to boost the use of testing and antiviral treatments in less wealthy countries, and a flurry of new funding pledges from organizations and companies alike.
You may also be interested in...
With efforts continuing to maximize access to medical countermeasures against the pandemic threat, a webinar organized by NGOs looked at progress with and the shortcomings of the WHO’s C-TAP initiative, recent moves by the WHO on access provisions in funding agreements, and plans for a global C-TAP database.
Coronavirus Notebook: Global COVID-19 Summit To Press For More Funding For Vaccines & Treatments, WHO Calls For End To IP Waiver ‘Stalemate’
CEPI has announced funding for a “variant-proof” vaccine being developed by a multidisciplinary consortium. The European Medicines Agency's new committee on drug shortages in health crises has held its first meeting, and the European Parliament’s new COVID-19 committee will quiz the health commissioner on the EU’s vaccines strategy and response to the pandemic.
EU member state authorities have been told they can use Jynneos, the US version of Bavarian Nordic’s smallpox vaccine, for the prevention of monkeypox. The bloc is also buying some 110,000 doses of the vaccine, with deliveries expected to begin shortly.